Genetic epidemiology of BRCA1

Cancer Biology and Therapy

Volumn 3, Issue 6, 2004, Pages 509-514

  Couch, Fergus J ^a  

^a MAYO CLINIC   (United States)

Author keywords

BRCA1; Breast cancer; Ovarian cancer; Tumor suppressor

Indexed keywords

BRCA1 PROTEIN;

ANALYTIC METHOD; CANCER RISK; CARCINOGENESIS; GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; HUMAN; MEDICAL INFORMATION; NONHUMAN; PREVALENCE; PROTEIN PROTEIN INTERACTION; REVIEW; BREAST TUMOR; EPIDEMIOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

BRCA1 PROTEIN; BREAST NEOPLASMS; EPIDEMIOLOGY, MOLECULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 9644261787     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.6.840     Document Type: Review

References (48)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian-cancer susceptibility gene Brca1. Science 1994; 206:66-71.
2. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: An evolutionary approach. Proc Natl Acad Sci USA 2003; 100:1151-6.
3. Ramirez CJ, Fleming MA, Potter JD, Ostrander GK, Ostrander EA. Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes. Oncogene 2004; 23:1780-8.
4. Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 2000; 67:841-50.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Haites N, et al. Risks of cancer in Brca1-mutation carriers. Lancet 1994; 343:692-5.
6. Ford D, Easton DF, Peto J. Estimates of the gene-frequency of Brca1 and its contribution to breast and ovarian-cancer incidence. Am J Hum Genet 1995; 57:1457-62.
7. Easton DF, Ford D, Bishop DT, Haites N, Milner B, Allan L, et al. Breast and ovarian-cancer incidence in Brca1-mutation carriers. Am J Hum Genet 1995; 56:265-71.
8. Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BAJ, et al. High allele loss Rates at 17Q12-Q21 in breast and ovarian-tumors from Brca1-linked families. Genes Chromosomes Cancer 1995; 13:203-10.
9. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18:1957-65.
10. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 2000; 60:5329-33.
11. Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of Brca1. Lancet 1994; 344:761-1.
12. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-8.
13. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60:496-504.
14. Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MBE, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159-64.
15. King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-6.
16. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002; 2:113-23.
17. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline Mutations of the BRCA1 gene in breast and ovarian-cancer families provide evidence for A Genotype-Phenotype Correlation. Nat Genet 1995; 11:428-33.
18. Rebbeck TR. Inherited predisposition and breast cancer: Modifiers of BRCA1/2-associated breast cancer risk. Environmental and Molecular Mutagenesis 2002; 39:228-34.
19. Rebbeck TR, Kantoff PN, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999; 64:1371-7.
20. Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R. Androgen receptor CAG repeats length in Jewish Israeli women who are BRCA1/2 mutation carriers: relevance to breast/ovarian cancer morbidity. Am J Hum Genet 2001; 69:248-8.
21. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: Results from a case series. Cancer Res 2001; 61:908-11.
22. Rebbeck TR, Wang YT, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001; 61:5420-4.
23. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the Hras1 minisatellite locus. N Engl J Med 1993; 329:517-23.
24. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996; 12:309-11.
25. Jakubowska A, Narod SA, Goldgar DE, Mierzejewski M, Masojc B, Nej K et al. Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol Biomarkers Prev 2003; 12:457-9.
26. Ginolhac SM, Gad S, Corbex M, Bressac-de-Paillerets B, Chompret A, Bignon YJ, et al. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidemiol Biomarkers Prev 2003; 12:90-5.
27. Thompson D and Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358-65.
28. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365-72.
29. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2004; 96:15-21.
30. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2004; 96:68-70.
31. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, et al. Detection of 8 Brca1 mutations in 10 breast ovarian-cancer families, including 1 family with male breast-cancer. Am J Hum Genet 1995; 57:1-7.
32. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the Brca1 185Delag mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nat Genet 1995; 11:198-200.
33. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20:1480-90.
34. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002; 11:329-36.
35. Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700-10.
36. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996; 56:471-4.
37. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349:1505-10.
38. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310-8.
39. Vaziri SAJ, Tubbs RR, Darlington G, Casey G. Absence of CCND 1 gene amplification in breast tumours of BRCA1 mutation carriers. J Clin Pathol-Mol Pathol 2001; 54:259-63.
40. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, et al. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res 2000; 60:5323-8.
41. Sinclair CS, Adem C, Naderi A, Soderberg CL, Johnson M, Wu KJ, et al. TBX2 is preferentially amplified in BRCA1- and BCRA2-related breast tumors. Cancer Res 2002; 62:3587-91.
42. Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, et al. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001; 7:831-8.
43. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482-5.
44. Hedenfalk I, Ringner M, Ben Dor A, Yakhini Z, Chen Y, Chebil G, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003; 100:2532-7.
45. van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
46. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57:1222-7.
47. Weaver Z, Montagna C, Xu XL, Howard T, Gadina M, Brodie SG, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002; 21:5097-107.
48. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (1). N Engl J Med 1992; 327:319-28.